Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Ann Oncol. 2015 Sep;26(9):1883-1889. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23.
Ann Oncol. 2015.
PMID: 26105600
Free article.
Clinical Trial.
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Oo ZY, Proctor M, Stevenson AJ, Nazareth D, Fernando M, Daignault SM, Lanagan C, Walpole S, Bonazzi V, Škalamera D, Snell C, Haass NK, Larsen JE, Gabrielli B.
Oo ZY, et al.
Mol Oncol. 2019 Jul;13(7):1503-1518. doi: 10.1002/1878-0261.12497. Epub 2019 Jun 14.
Mol Oncol. 2019.
PMID: 31044505
Free PMC article.
Item in Clipboard
Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours.
Fernando M, Duijf PHG, Proctor M, Stevenson AJ, Ehmann A, Vora S, Skalamera D, Adams M, Gabrielli B.
Fernando M, et al.
Oncogenesis. 2021 May 15;10(5):41. doi: 10.1038/s41389-021-00329-8.
Oncogenesis. 2021.
PMID: 33993200
Free PMC article.
Item in Clipboard
Cite
Cite